Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain
Antipsychotics are an essential component in the treatment of schizophrenia. Long-acting injectable formulations (LAI) arose to improve adherence with the associated potential of reducing the risk of relapse. The objective of this article is to analyze the use of LAI antipsychotics in Spain, which i...
Gespeichert in:
| Veröffentlicht in: | Revista de psiquiatria y salud mental 2019-04, Vol.12 (2), p.92-105 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng ; spa |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 105 |
|---|---|
| container_issue | 2 |
| container_start_page | 92 |
| container_title | Revista de psiquiatria y salud mental |
| container_volume | 12 |
| creator | Arango, Celso Baeza, Inmaculada Bernardo, Miquel Cañas, Fernando de Dios, Consuelo Díaz-Marsá, Marina García-Portilla, María Paz Gutiérrez-Rojas, Luis Olivares, José Manuel Rico-Villademoros, Fernando Rodríguez-Jiménez, Roberto Sánchez-Morla, Eva María Segarra, Rafael Crespo-Facorro, Benedicto |
| description | Antipsychotics are an essential component in the treatment of schizophrenia. Long-acting injectable formulations (LAI) arose to improve adherence with the associated potential of reducing the risk of relapse. The objective of this article is to analyze the use of LAI antipsychotics in Spain, which is similar to other European countries but with a predominance of the use of second generation LAI, to discuss the possible causes of prescribing differences with respect to other countries (including organizational aspects, attitudes of psychiatrists, patients and family members, and clinical practice guidelines), and to discuss their use in acute psychiatric units, first episode, and in children and adolescents. In our view, while it is necessary to increase existing evidence regarding the advantages of LAI antipsychotics and the differentiation between LAI antipsychotics currently available, their use will likely continue to grow driven by clinical experience. |
| doi_str_mv | 10.1016/j.rpsm.2018.03.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2062834337</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2062834337</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-b200653d9939a1d26ef6b7ddeca989474fca1da9bb07b2f509f29f6bfc6143ae3</originalsourceid><addsrcrecordid>eNo1kE1LAzEURYMgtmj_gAvJ0s2M-WpmspTiFxRE1PWQZJJOykwSk3RRf70j1rd58Dj3cbgAXGNUY4T53b5OMU81QbitEa0R4mdgiUUrKsYRWoBVzns0D1_jFrELsCBCrFmDmiV42wa_q6Quzu-g83uji1SjgdIXF_NRD6E4naENCZbBwJKMLJPxBQYLsx7cd4hDMt7JOQzfo3T-CpxbOWazOu1L8Pn48LF5rravTy-b-20VCcalUuTXh_ZCUCFxT7ixXDV9b7ScxVnDrJ7PUiiFGkXsGglLxIxYzTGj0tBLcPv3N6bwdTC5dJPL2oyj9CYcckcQJy1llDYzenNCD2oyfReTm2Q6dv810B8qPGB9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2062834337</pqid></control><display><type>article</type><title>Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Arango, Celso ; Baeza, Inmaculada ; Bernardo, Miquel ; Cañas, Fernando ; de Dios, Consuelo ; Díaz-Marsá, Marina ; García-Portilla, María Paz ; Gutiérrez-Rojas, Luis ; Olivares, José Manuel ; Rico-Villademoros, Fernando ; Rodríguez-Jiménez, Roberto ; Sánchez-Morla, Eva María ; Segarra, Rafael ; Crespo-Facorro, Benedicto</creator><creatorcontrib>Arango, Celso ; Baeza, Inmaculada ; Bernardo, Miquel ; Cañas, Fernando ; de Dios, Consuelo ; Díaz-Marsá, Marina ; García-Portilla, María Paz ; Gutiérrez-Rojas, Luis ; Olivares, José Manuel ; Rico-Villademoros, Fernando ; Rodríguez-Jiménez, Roberto ; Sánchez-Morla, Eva María ; Segarra, Rafael ; Crespo-Facorro, Benedicto</creatorcontrib><description>Antipsychotics are an essential component in the treatment of schizophrenia. Long-acting injectable formulations (LAI) arose to improve adherence with the associated potential of reducing the risk of relapse. The objective of this article is to analyze the use of LAI antipsychotics in Spain, which is similar to other European countries but with a predominance of the use of second generation LAI, to discuss the possible causes of prescribing differences with respect to other countries (including organizational aspects, attitudes of psychiatrists, patients and family members, and clinical practice guidelines), and to discuss their use in acute psychiatric units, first episode, and in children and adolescents. In our view, while it is necessary to increase existing evidence regarding the advantages of LAI antipsychotics and the differentiation between LAI antipsychotics currently available, their use will likely continue to grow driven by clinical experience.</description><identifier>EISSN: 1989-4600</identifier><identifier>EISSN: 2173-5050</identifier><identifier>DOI: 10.1016/j.rpsm.2018.03.006</identifier><identifier>PMID: 29954707</identifier><language>eng ; spa</language><publisher>Spain</publisher><subject>Antipsychotic Agents - administration & dosage ; Antipsychotic Agents - therapeutic use ; Delayed-Action Preparations ; Drug Utilization - trends ; Humans ; Injections, Intramuscular ; Practice Patterns, Physicians' - trends ; Schizophrenia - drug therapy ; Spain ; Treatment Outcome</subject><ispartof>Revista de psiquiatria y salud mental, 2019-04, Vol.12 (2), p.92-105</ispartof><rights>Copyright © 2018 SEP y SEPB. Publicado por Elsevier España, S.L.U. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29954707$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arango, Celso</creatorcontrib><creatorcontrib>Baeza, Inmaculada</creatorcontrib><creatorcontrib>Bernardo, Miquel</creatorcontrib><creatorcontrib>Cañas, Fernando</creatorcontrib><creatorcontrib>de Dios, Consuelo</creatorcontrib><creatorcontrib>Díaz-Marsá, Marina</creatorcontrib><creatorcontrib>García-Portilla, María Paz</creatorcontrib><creatorcontrib>Gutiérrez-Rojas, Luis</creatorcontrib><creatorcontrib>Olivares, José Manuel</creatorcontrib><creatorcontrib>Rico-Villademoros, Fernando</creatorcontrib><creatorcontrib>Rodríguez-Jiménez, Roberto</creatorcontrib><creatorcontrib>Sánchez-Morla, Eva María</creatorcontrib><creatorcontrib>Segarra, Rafael</creatorcontrib><creatorcontrib>Crespo-Facorro, Benedicto</creatorcontrib><title>Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain</title><title>Revista de psiquiatria y salud mental</title><addtitle>Rev Psiquiatr Salud Ment</addtitle><description>Antipsychotics are an essential component in the treatment of schizophrenia. Long-acting injectable formulations (LAI) arose to improve adherence with the associated potential of reducing the risk of relapse. The objective of this article is to analyze the use of LAI antipsychotics in Spain, which is similar to other European countries but with a predominance of the use of second generation LAI, to discuss the possible causes of prescribing differences with respect to other countries (including organizational aspects, attitudes of psychiatrists, patients and family members, and clinical practice guidelines), and to discuss their use in acute psychiatric units, first episode, and in children and adolescents. In our view, while it is necessary to increase existing evidence regarding the advantages of LAI antipsychotics and the differentiation between LAI antipsychotics currently available, their use will likely continue to grow driven by clinical experience.</description><subject>Antipsychotic Agents - administration & dosage</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Delayed-Action Preparations</subject><subject>Drug Utilization - trends</subject><subject>Humans</subject><subject>Injections, Intramuscular</subject><subject>Practice Patterns, Physicians' - trends</subject><subject>Schizophrenia - drug therapy</subject><subject>Spain</subject><subject>Treatment Outcome</subject><issn>1989-4600</issn><issn>2173-5050</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE1LAzEURYMgtmj_gAvJ0s2M-WpmspTiFxRE1PWQZJJOykwSk3RRf70j1rd58Dj3cbgAXGNUY4T53b5OMU81QbitEa0R4mdgiUUrKsYRWoBVzns0D1_jFrELsCBCrFmDmiV42wa_q6Quzu-g83uji1SjgdIXF_NRD6E4naENCZbBwJKMLJPxBQYLsx7cd4hDMt7JOQzfo3T-CpxbOWazOu1L8Pn48LF5rravTy-b-20VCcalUuTXh_ZCUCFxT7ixXDV9b7ScxVnDrJ7PUiiFGkXsGglLxIxYzTGj0tBLcPv3N6bwdTC5dJPL2oyj9CYcckcQJy1llDYzenNCD2oyfReTm2Q6dv810B8qPGB9</recordid><startdate>201904</startdate><enddate>201904</enddate><creator>Arango, Celso</creator><creator>Baeza, Inmaculada</creator><creator>Bernardo, Miquel</creator><creator>Cañas, Fernando</creator><creator>de Dios, Consuelo</creator><creator>Díaz-Marsá, Marina</creator><creator>García-Portilla, María Paz</creator><creator>Gutiérrez-Rojas, Luis</creator><creator>Olivares, José Manuel</creator><creator>Rico-Villademoros, Fernando</creator><creator>Rodríguez-Jiménez, Roberto</creator><creator>Sánchez-Morla, Eva María</creator><creator>Segarra, Rafael</creator><creator>Crespo-Facorro, Benedicto</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201904</creationdate><title>Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain</title><author>Arango, Celso ; Baeza, Inmaculada ; Bernardo, Miquel ; Cañas, Fernando ; de Dios, Consuelo ; Díaz-Marsá, Marina ; García-Portilla, María Paz ; Gutiérrez-Rojas, Luis ; Olivares, José Manuel ; Rico-Villademoros, Fernando ; Rodríguez-Jiménez, Roberto ; Sánchez-Morla, Eva María ; Segarra, Rafael ; Crespo-Facorro, Benedicto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-b200653d9939a1d26ef6b7ddeca989474fca1da9bb07b2f509f29f6bfc6143ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; spa</language><creationdate>2019</creationdate><topic>Antipsychotic Agents - administration & dosage</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Delayed-Action Preparations</topic><topic>Drug Utilization - trends</topic><topic>Humans</topic><topic>Injections, Intramuscular</topic><topic>Practice Patterns, Physicians' - trends</topic><topic>Schizophrenia - drug therapy</topic><topic>Spain</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arango, Celso</creatorcontrib><creatorcontrib>Baeza, Inmaculada</creatorcontrib><creatorcontrib>Bernardo, Miquel</creatorcontrib><creatorcontrib>Cañas, Fernando</creatorcontrib><creatorcontrib>de Dios, Consuelo</creatorcontrib><creatorcontrib>Díaz-Marsá, Marina</creatorcontrib><creatorcontrib>García-Portilla, María Paz</creatorcontrib><creatorcontrib>Gutiérrez-Rojas, Luis</creatorcontrib><creatorcontrib>Olivares, José Manuel</creatorcontrib><creatorcontrib>Rico-Villademoros, Fernando</creatorcontrib><creatorcontrib>Rodríguez-Jiménez, Roberto</creatorcontrib><creatorcontrib>Sánchez-Morla, Eva María</creatorcontrib><creatorcontrib>Segarra, Rafael</creatorcontrib><creatorcontrib>Crespo-Facorro, Benedicto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Revista de psiquiatria y salud mental</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arango, Celso</au><au>Baeza, Inmaculada</au><au>Bernardo, Miquel</au><au>Cañas, Fernando</au><au>de Dios, Consuelo</au><au>Díaz-Marsá, Marina</au><au>García-Portilla, María Paz</au><au>Gutiérrez-Rojas, Luis</au><au>Olivares, José Manuel</au><au>Rico-Villademoros, Fernando</au><au>Rodríguez-Jiménez, Roberto</au><au>Sánchez-Morla, Eva María</au><au>Segarra, Rafael</au><au>Crespo-Facorro, Benedicto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain</atitle><jtitle>Revista de psiquiatria y salud mental</jtitle><addtitle>Rev Psiquiatr Salud Ment</addtitle><date>2019-04</date><risdate>2019</risdate><volume>12</volume><issue>2</issue><spage>92</spage><epage>105</epage><pages>92-105</pages><eissn>1989-4600</eissn><eissn>2173-5050</eissn><abstract>Antipsychotics are an essential component in the treatment of schizophrenia. Long-acting injectable formulations (LAI) arose to improve adherence with the associated potential of reducing the risk of relapse. The objective of this article is to analyze the use of LAI antipsychotics in Spain, which is similar to other European countries but with a predominance of the use of second generation LAI, to discuss the possible causes of prescribing differences with respect to other countries (including organizational aspects, attitudes of psychiatrists, patients and family members, and clinical practice guidelines), and to discuss their use in acute psychiatric units, first episode, and in children and adolescents. In our view, while it is necessary to increase existing evidence regarding the advantages of LAI antipsychotics and the differentiation between LAI antipsychotics currently available, their use will likely continue to grow driven by clinical experience.</abstract><cop>Spain</cop><pmid>29954707</pmid><doi>10.1016/j.rpsm.2018.03.006</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1989-4600 |
| ispartof | Revista de psiquiatria y salud mental, 2019-04, Vol.12 (2), p.92-105 |
| issn | 1989-4600 2173-5050 |
| language | eng ; spa |
| recordid | cdi_proquest_miscellaneous_2062834337 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Antipsychotic Agents - administration & dosage Antipsychotic Agents - therapeutic use Delayed-Action Preparations Drug Utilization - trends Humans Injections, Intramuscular Practice Patterns, Physicians' - trends Schizophrenia - drug therapy Spain Treatment Outcome |
| title | Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T17%3A38%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-acting%20injectable%20antipsychotics%20for%20the%20treatment%20of%20schizophrenia%20in%20Spain&rft.jtitle=Revista%20de%20psiquiatria%20y%20salud%20mental&rft.au=Arango,%20Celso&rft.date=2019-04&rft.volume=12&rft.issue=2&rft.spage=92&rft.epage=105&rft.pages=92-105&rft.eissn=1989-4600&rft_id=info:doi/10.1016/j.rpsm.2018.03.006&rft_dat=%3Cproquest_pubme%3E2062834337%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2062834337&rft_id=info:pmid/29954707&rfr_iscdi=true |